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Is Early Carotid Stenting Indicated in Patients with
Recent Neurological Events?Although it is well recognized that surgical carotid re-
vascularization is the treatment of choice in symptomatic
carotid artery stenosis, the role of early intervention in
patients with recent neurological events is still a controver-
sial issue. Catastrophic outcomes reported in the first
anedoctal cases of urgent carotid surgery in unselected
patients presenting with stroke have influenced the ‘‘con-
ventional teaching’’ that patients suffering stroke should
wait 6-8 weeks for revascularization. However, recent data
from population-based studies1 has revealed that the risk of
recurrent stroke is up to 10% in the week after a transient
ischaemic attack (TIA) or minor stroke. The prevention of
recurrent strokes in the penumbra zone and the minimiza-
tion of the incidence of reperfusion injury are the most im-
portant factors in the treatment of patients with acute
stroke. The disapproval of early treatment after an acute
stroke is inappropriate, as demonstrated by the analysis
of pooled data from the randomized controlled trials of
endarterectomy for symptomatic carotid stenosis.2 These
data clearly showed that benefit from endarterectomy
depends not only on the degree of carotid stenosis, but
also on delay to surgery after the index event (ideally,
the procedure should be performed within 2 weeks).
An Italian multicenter study - The Surgical Treatment of
Acute Cerebral Ischemia (STACI)3e has recently shown
that patients whose neuroimaging studies in the early hours
after stroke document a recent, limited cerebral infarction
can safely undergo very early CEA (1.5 days after stroke)
with similar risk to elective surgery.
There are now several guidelines in this direction: the
National UK Stroke Strategy,4 the American Academy of
Neurology (AAN)5 and the American Heart Association
(AHA)6 recommend treatment within two weeks in patients
presenting with a transient ischaemic attack (TIA) or a non-
disabling stroke. The Italian SPREAD7 (Stroke Prevention and
Educational Awareness Diffusion) guideline clearly states
that carotid surgery is recommended as early as possible
(within 2 weeks of the event) for patients with TIA, minor
stroke or stabilized neurological deficit with normal CT
scanning or minimal lesions (Grade A recommendation).1078-5884/$34 ª 2008 European Society for Vascular Surgery. Publishe
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as a useful and potentially less invasive alternative to carotid
endarterectomy (CEA) for the treatment of extracranial
carotid stenosis in high risk patients. So far operators’
experience has grown, techniques refined and indications
extended. Although definitive scientific proof has still not
been obtained fromRCTs, after the publication of the EVA-3S8
and SPACE9 Trials, despite the vivid debate questioning the
safety of CAS, there is an increasing number of reports by
endovascular specialists that consider CAS equivalent to CEA.
However, principally in Europe, some surgeons/inter-
ventionists have based this feeling on treatment of a vast
number of asymptomatic patients, while currently one of
the most challenging questions is whether CAS could be
offered to patients with acute neurologic symptoms. The
major concerns regarding this possibility are two: first,
cerebral revascularization in the acute stage remains
challenging because of the possibility that hemorrhagic
infarction or hyperperfusion syndrome will occur after
revascularization; second, alarm about CAS in symptomatic
patients is related to the general feeling that the remodel-
ing of these vulnerable plaques by the stent might be at
high risk of cerebral embolization.
The first point really still affects the median delay from
the index event to surgery in real world practice. Most
specialists involved in stroke care are reluctant to undertake
carotid revascularization immediately after the onset of
stroke for fear that hemorrhagic transformation of the
cerebral infarct may increase the procedural risk, and offer
surgery only after 2e4 weeks. Moreover, many emergency
rooms are inadequately resourced to perform early treat-
ment. According to Naylor10 a ‘‘delay’’ in the treatment
‘‘may reduce procedural risk, but at what price to the pa-
tient?’’. Analysis of data from the Carotid Endarterectomy
Trialists Collaboration database2 (more than 6000 symptom-
atic patients with carotid stenosis) clearly reveals that the
price is paid by the cohort of patients operated on with a de-
lay >2 weeks, in terms of less strokes prevented at 5 years.
There is insufficient evidence to predict which patients
with severe carotid stenosis associated with recent stroked by Elsevier Ltd. All rights reserved.
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distal site of the vascular lesion and a number of exclusion
criteria for early treatment should be taken into account;
patient subgroups in which early surgery should be avoided
include those with evidence: of ischaemic infarct >2.5 cm
in diameter, of intracranial haemorrhage, of recent carotid
occlusion (lasted >6 hrs), Rankin score >3, fluctuating level
of consciousness and no neurological plateau. However, in
correctly selected patients early treatment reduces the
recurrent stroke rate, and is recommended as soon as pos-
sible from the index event.
The second main concern about CAS in patients with acute
symptoms is related to the fact that while with CEA the
plaque is completely removed, after stenting it is only
remodelled and its stabilization is essential to avoid embolic
events during the procedure and in the post-operative period.
For these reasons part of debate now revolves around
the stent properties, in particular the important role of
scaffolding of the emboligenic plaque by the struts of the
stent.11,12 This message has particularly been understood
by many companies, which are now working on a next
generation stent that prioritizes scaffolding improvement.
Another part of the discussion concerns the importance of
cerebral protection systems during CAS, with particular
emphasis on evaluating the efficacy and safety of proximal
occlusive devices in minimizing cerebral embolization from
the vulnerable plaques during the procedure.
With regard to patient selection based on neurological
status and instrumental findings, a recently published
prospectivemulticenter registry - the ‘‘Submarine Study’’13-
indicated that early treatment with protected carotid stent-
ing is both feasible and safe in selected patients with first
episode or recurrent TIA or minor stroke. Although in a lim-
ited series of patients (nZ 57), this preliminary study
revealed that endovascular treatment has a satisfactory out-
come considering the very high risk profile of the patient
population (at 30 days: death 1.7%, TIA/stroke 3.5%). More-
over the evaluation of some brain ischemia biomarkers (in
particular PAPP-A, hs-CR, and IL-6) in this cohort of patients
suggested an inflammatory role for them in the process of an
unstable carotid plaque generating an acute cerebral event.
These vulnerabilitymarkers could be useful attempts to non-
invasively identify vulnerable plaques at early stages, and
before the onset of an acute clinical event.References
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